Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Camostat mesilate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44363   clinical trials with a EudraCT protocol, of which   7387   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6 result(s) found for: Camostat mesilate. Displaying page 1 of 1.
    EudraCT Number: 2020-002110-41 Sponsor Protocol Number: CRUKD/20/002 Start Date*: 2020-06-18
    Sponsor Name:Cancer Research UK
    Full Title: SPIKE-1 TRIAL: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated memb...
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-002233-15 Sponsor Protocol Number: NICCAM-001 Start Date*: 2020-06-17
    Sponsor Name:Charité Research Organisation GmbH
    Full Title: A randomized, single blind, placebo-controlled, multiple dose, parallel-arm study to investigate the safety and preliminary efficacy of the combination of Niclosamide and Camostat to treat COVID-19...
    Medical condition: SARS-Coronavirus 2 disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003366-39 Sponsor Protocol Number: APHP200702 Start Date*: 2020-10-16
    Sponsor Name:Assitance Publique-Hopiaux de Paris
    Full Title: CAMOVID: A multicenter randomized trial to evaluate the efficacy and safety of camostat mesylate for the treatment of SARS-CoV-2 infection in ambulatory adult patients.
    Medical condition:
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001200-42 Sponsor Protocol Number: CamoCO-19-001 Start Date*: 2020-03-30
    Sponsor Name:Department of Infecitous Diseases, Aarhus University Hospital
    Full Title: The Impact of Camostat Mesilate on COVID-19 Infection: An investigator-initiated randomized, placebo-controlled, phase IIa trial
    Medical condition: 2019-nCoV acute respiratory disease
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003475-18 Sponsor Protocol Number: COV-AAT Start Date*: 2020-10-21
    Sponsor Name:Ghent University Hospital
    Full Title: The potential of oral Camostat in early COVID-19 disease in an ambulatory setting to reduce viral load and disease burden.
    Medical condition: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005911-27 Sponsor Protocol Number: S64445 Start Date*: 2021-03-17
    Sponsor Name:KU Leuven
    Full Title: The DAWN antivirals trial: the efficacy of antivirals for COVID-19 infections presenting to ambulatory care: a randomized controlled trial.
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Nov 04 13:07:00 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA